Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant penpulimab after nephrectomy for very-high-risk clear cell renal cell carcinoma
ChiCTR2200062189Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of penpulimab in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Disease-free survival. Started Jul 2022; status: completed.
02
Drugs
penpulimab
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2200062189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062189.